Skip to main content
AmgenPatent grant

Amgen was granted a patent for treating homozygous familial hypercholesterolemia.

Source: Autobound Signal API · 83 signals tracked for Amgen · updated

Get Amgen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Amgen this week? Use Autobound signals for amgen.com.

What happened

In November 2026 Amgen patented an antibody-based treatment approach for lowering cholesterol in people with severe inherited high cholesterol, including clinical care settings.

Source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Nov 17, 2026
Inventors
3
Patent number
US12799227
Assignee
AMGEN INC.

The full record

From the Signal API record

People

  • Scott WassermanInventor
  • Robert Andrew Donald ScottInventor
  • Evan A. SteinInventor

Details

Primary CPC class
C07K 16/40
USPTO assignee
AMGEN INC.
What the invention does
A treatment method that uses antibodies blocking PCSK9, a protein that limits the liver’s ability to remove LDL cholesterol from the blood.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Pharmaceuticals
  • Medical Research

Technologies named

  • PCSK9 antibodies
  • antibody therapeutics
  • cholesterol treatment

Extraction

Detected
Nov 18, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for Amgen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/762383ba-eb29-5ef9-a6d2-4d9abd5a1486 returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.

{
  "signal_id": "762383ba-eb29-5ef9-a6d2-4d9abd5a1486",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-11-18T15:08:10+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07K 16/40"
      },
      {
        "code": "A61K 2039/505"
      },
      {
        "code": "C07K 2317/76"
      },
      {
        "code": "C07K 2317/92"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In November 2026 Amgen patented an antibody-based treatment approach for lowering cholesterol in people with severe inherited high cholesterol, including clinical care settings.",
    "summary": "Amgen was granted a patent for treating homozygous familial hypercholesterolemia.",
    "event_at": "2026-11-17",
    "inventors": [
      {
        "name": "Scott Wasserman",
        "status": "unresolved",
        "is_primary": true
      },
      {
        "name": "Robert Andrew Donald Scott",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Evan A. Stein",
        "status": "unresolved",
        "is_primary": false
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-11-17",
    "source_url": "https://patents.google.com/patent/US12799227",
    "cpc_primary": {
      "code": "C07K 16/40"
    },
    "patent_title": "Methods for treating homozygous familial hypercholesterolemia",
    "patent_number": "US12799227",
    "uspto_assignee": "AMGEN INC.",
    "patent_abstract": "The present invention relates to methods for treating homozygous familial hypercholesterolemia using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9).",
    "precision_class": "structural",
    "invention_explanation": "A treatment method that uses antibodies blocking PCSK9, a protein that limits the liver’s ability to remove LDL cholesterol from the blood.",
    "technologies_mentioned": [
      "PCSK9 antibodies",
      "antibody therapeutics",
      "cholesterol treatment"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.